 |
77 Diseases |  |
69 Trials |
|
69 Trials |  |
4434 News |  |
| «12...34353637383940414243444546» |
- ||||||| Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial completion: Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF (clinicaltrials.gov) - Nov 6, 2014
P3, N=482, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion, Trial primary completion date: Changes in Insulin Resistance in Healthy Volunteers on STRIBILD (clinicaltrials.gov) - Nov 5, 2014
P1, N=30, Completed, Sponsor: Technische Universit
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Oct 2014
- lopinavir/ritonavir / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents (clinicaltrials.gov) - Oct 30, 2014
P4, N=4, Terminated, Sponsor: Children's Research Institute
Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Oct 2014 N=78 --> 4 | Completed --> Terminated | Trial primary completion date: Aug 2008 --> May 2009; no measurable response was detected at the 50% increase threshold.
- || abacavir/lamivudine/zidovudine / Generic mfg., abacavir/lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe (clinicaltrials.gov) - Oct 30, 2014
P2/3, N=49, Completed, Sponsor: Parirenyatwa Hospital
N=78 --> 4 | Completed --> Terminated | Trial primary completion date: Aug 2008 --> May 2009; no measurable response was detected at the 50% increase threshold. Active, not recruiting --> Completed
- nevirapine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change: PROMISE: Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=3485, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=5900 --> 3485
- | NN1213 / Novo Nordisk
Trial completion: When to Start Anti-HIV Drugs in Patients With Opportunistic Infections (clinicaltrials.gov) - Oct 15, 2014
P4, N=283, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=5900 --> 3485 No longer recruiting --> Completed
- nevirapine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed: PROMISE: Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=5900, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- | lopinavir/ritonavir / Generic mfg.
New P1 trial: Study of Pharmacokinetic Interaction Between Kaletra (clinicaltrials.gov) - Oct 10, 2014
P1, N=34, Completed, Sponsor: Boehringer Ingelheim
- |||| Isentress (raltegravir) / Merck (MSD)
Enrollment open: RANIA: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (clinicaltrials.gov) - Oct 2, 2014
P2, N=100, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF (clinicaltrials.gov) - Sep 28, 2014
P3, N=660, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Isentress (raltegravir) / Merck (MSD)
Trial completion: SPARE: Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=59, Completed, Sponsor: National Center for Global Health and Medicine, Japan
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: NRTI-Sparing Pilot Study (clinicaltrials.gov) - Sep 28, 2014
P4, N=13, Completed, Sponsor: University of British Columbia
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=76 --> 13 | Trial primary completion date: Dec 2013 --> Feb 2008
- efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: LIPOKAL: Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (clinicaltrials.gov) - Sep 19, 2014
P4, N=20, Completed, Sponsor: Juan A. Arnaiz
Active, not recruiting --> Completed | N=76 --> 13 | Trial primary completion date: Dec 2013 --> Feb 2008 Active, not recruiting --> Completed
- || lopinavir/ritonavir / Generic mfg.
Enrollment closed: Surveillance of Kaletra in Korean Patients (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=555, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- || tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P3 trial, Combination therapy: Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults (clinicaltrials.gov) - Sep 5, 2014
P3, N=65, Recruiting, Sponsor: Yongtao Sun, MD, PhD
- |||||||||| Tivicay (dolutegravir) / ViiV Healthcare
New P3 trial: Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment (clinicaltrials.gov) - Aug 29, 2014
P3, N=612, Not yet recruiting, Sponsor: ViiV Healthcare
- |||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: ARKS: Anti-Retrovirals for Kaposi's Sarcoma (clinicaltrials.gov) - Aug 21, 2014
P4, N=224, Completed, Sponsor: University of California, San Francisco
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
New P3 trial: Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection (clinicaltrials.gov) - Aug 19, 2014
P3, N=18, Recruiting, Sponsor: Peking Union Medical College
- | Daklinza (daclatasvir) / BMS
Trial completion: Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants (clinicaltrials.gov) - Aug 12, 2014
P1, N=28, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Recruiting --> Completed
- nevirapine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed, Trial primary completion date: Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Populations Using Formula Feeding (PROMISE) (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=1000, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Sep 2016
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P1 trial: Changes in Insulin Resistance in Healthy Volunteers on STRIBILD (clinicaltrials.gov) - Jul 30, 2014
P1, N=30, Recruiting, Sponsor: Technische Universit
- emtricitabine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, Enrollment change: Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression (clinicaltrials.gov) - Jul 30, 2014
P4, N=250, Completed, Sponsor: Juan A. Arnaiz
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Sep 2016 Recruiting --> Completed | N=336 --> 250
- zidovudine / Generic mfg., nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial termination: PHPT-5: Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand (clinicaltrials.gov) - Jul 27, 2014
P3, N=2097, Terminated, Sponsor: Institut de Recherche pour le Developpement
Recruiting --> Completed | N=336 --> 250 Active, not recruiting --> Terminated; Change in National PMTCT guidelines in Thailand
- || lopinavir/ritonavir / Generic mfg.
Trial primary completion date, Combination therapy: PROTEKT: Kaletra in Combination With Antiretroviral Agents (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=450, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Terminated; Change in National PMTCT guidelines in Thailand Trial primary completion date: Dec 2018 --> Dec 2017
- || lopinavir/ritonavir / Generic mfg.
Enrollment change, Trial primary completion date, Adherence: Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=165, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2018 --> Dec 2017 N=240 --> 165 | Trial primary completion date: Jun 2015 --> Dec 2015
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P4 trial: STRIB-PEP: Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada (clinicaltrials.gov) - Jul 23, 2014
P4, N=160, Not yet recruiting, Sponsor: Fundacion Clinic per a la Recerca Biom
- Selzentry (maraviroc) / ViiV Healthcare
Enrollment change, Trial primary completion date: MARCH Central Nervous System Substudy (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=28, Active, not recruiting, Sponsor: Kirby Institute
N=240 --> 165 | Trial primary completion date: Jun 2015 --> Dec 2015 N=50 --> 28 | Trial primary completion date: Oct 2014 --> Jan 2015
- |||||| Prezista (darunavir) / J&J
Enrollment open, Monotherapy: MANET: Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS (clinicaltrials.gov) - Jul 17, 2014
P3, N=150, Recruiting, Sponsor: University of Liverpool
N=50 --> 28 | Trial primary completion date: Oct 2014 --> Jan 2015 Active, not recruiting --> Recruiting
- VRC07-523LS / National Institute of Allergy and Infectious Diseases, IAVI, TaiMed Biologics, VRC01 / Acuitas Therap
Enrollment open: Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (clinicaltrials.gov) - Jul 12, 2014
P1/2, N=472, Recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- rifampicin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial initiation date, Combination therapy: Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin (clinicaltrials.gov) - Jul 2, 2014
P4, N=12, Not yet recruiting, Sponsor: University of Miami
Not yet recruiting --> Recruiting Initiation date: Dec 2012 --> Apr 2014
- lopinavir/ritonavir / Generic mfg.
Trial primary completion date: IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children (clinicaltrials.gov) - Jun 27, 2014
P4, N=50, Not yet recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Initiation date: Dec 2012 --> Apr 2014 Trial primary completion date: Sep 2014 --> Jun 2015
- lopinavir/ritonavir / Generic mfg.
Trial initiation date, Trial primary completion date: IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children (clinicaltrials.gov) - Jun 27, 2014
P4, N=50, Not yet recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Trial primary completion date: Sep 2014 --> Jun 2015 Initiation date: Jan 2014 --> Sep 2014 | Trial primary completion date: Sep 2014 --> Jun 2015
- ||||||| emtricitabine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, Monotherapy: DREAM: Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients (clinicaltrials.gov) - Jun 27, 2014
P2/3, N=420, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Initiation date: Jan 2014 --> Sep 2014 | Trial primary completion date: Sep 2014 --> Jun 2015 Active, not recruiting --> Completed
- | Daklinza (daclatasvir) / BMS
New P1 trial: Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants (clinicaltrials.gov) - Jun 7, 2014
P1, N=28, Recruiting, Sponsor: Bristol-Myers Squibb
- Daklinza (daclatasvir) / BMS
Enrollment open: Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants (clinicaltrials.gov) - Jun 5, 2014
P1, N=28, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- lopinavir/ritonavir / Generic mfg.
Trial primary completion date: Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women (clinicaltrials.gov) - Jun 4, 2014
P2, N=25, Completed, Sponsor: AIDS Clinical Trials Group
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2013 --> Oct 2012
- lopinavir/ritonavir / Generic mfg.
Trial completion: Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women (clinicaltrials.gov) - Jun 4, 2014
P2, N=25, Completed, Sponsor: AIDS Clinical Trials Group
Trial primary completion date: Jun 2013 --> Oct 2012 Active, not recruiting --> Completed
- |||||||||| Prezista (darunavir) / J&J
New P3 trial, Monotherapy: MANET: Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS (clinicaltrials.gov) - Jun 2, 2014
P3, N=150, Active, not recruiting, Sponsor: University of Liverpool
- | Isentress (raltegravir) / Merck (MSD)
New P2b trial: FIT-2: First-Line Treatment for HIV-2 (clinicaltrials.gov) - May 27, 2014
P2b, N=210, Not yet recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- || lopinavir/ritonavir / Generic mfg.
Trial primary completion date: Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet (clinicaltrials.gov) - May 15, 2014
P=N/A, N=3000, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Trial primary completion date: Nov 2017 --> Dec 2017
- Trial primary completion date: IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults (clinicaltrials.gov) - May 15, 2014
P=N/A, N=168, Completed, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Trial primary completion date: Nov 2017 --> Dec 2017 Trial primary completion date: Dec 2015 --> Mar 2014
- | lopinavir/ritonavir / Generic mfg.
Trial completion date: Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet (clinicaltrials.gov) - May 15, 2014
P=N/A, N=3000, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2015 --> Mar 2014 Trial completion date: Nov 2017 --> Dec 2017
- Trial completion date: IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults (clinicaltrials.gov) - May 15, 2014
P=N/A, N=168, Completed, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Trial completion date: Nov 2017 --> Dec 2017 Trial completion date: May 2016 --> Mar 2014
- Trial completion: IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults (clinicaltrials.gov) - May 15, 2014
P=N/A, N=168, Completed, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Trial completion date: May 2016 --> Mar 2014 Active, not recruiting --> Completed
- | VRC07-523LS / National Institute of Allergy and Infectious Diseases, IAVI, TaiMed Biologics, VRC01 / Acuitas Therap
New P1/2 trial: Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (clinicaltrials.gov) - May 14, 2014
P1/2, N=472, Not yet recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- |||||| Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF (clinicaltrials.gov) - May 8, 2014
P3, N=660, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - May 5, 2014
P4, N=1300, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Trial primary completion date: May 2014 --> May 2016
- ||| Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial completion date: Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF (clinicaltrials.gov) - Apr 24, 2014
P3, N=482, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: May 2014 --> May 2016 Trial completion date: Mar 2014 --> Sep 2014
- |||||||||| Descovy (emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF (clinicaltrials.gov) - Apr 22, 2014
P3, N=660, Not yet recruiting, Sponsor: Gilead Sciences
- ||||| Isentress (raltegravir) / Merck (MSD)
New P2 trial: RANIA: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (clinicaltrials.gov) - Apr 15, 2014
P2, N=100, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.